Related Experiment Video

Updated: Jun 24, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.2K

Unlocking the Next Frontier in Precision Oncology: Addressing Drug-Tolerant Residual Disease

Jessica J Lin1, Justin F Gainor1, Vincent K Lam2

  • 1Department of Medicine and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts.

Cancer Discovery
|June 3, 2024
PubMed
Abstract

Insights

Drug-tolerant residual disease (DTRD) can cause acquired drug resistance in metastatic cancers. Targeting this residual disease state is crucial for advancing precision oncology and improving patient outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Pharmacology

Background:

  • Drug-tolerant residual disease (DTRD) poses a significant challenge in cancer therapy.
  • DTRD acts as a reservoir for acquired drug resistance.
  • This phenomenon impacts various cancers and therapeutic approaches.

Purpose of the Study:

  • To propose a paradigm shift in metastatic cancer treatment.
  • To focus on defining, monitoring, and targeting DTRD.
  • To advance precision oncology strategies.

Main Methods:

  • The abstract does not specify methods.
  • Further research is needed to define methodologies for DTRD monitoring and targeting.

Main Results:

  • The abstract does not specify results.
  • The study proposes a conceptual framework rather than presenting empirical findings.

Conclusions:

  • Addressing DTRD is essential for overcoming acquired drug resistance.
  • A strategic focus on DTRD is key to the future of precision oncology.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

10.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K